Hepatic risks of chemoprophylaxis
| Reference | N | Hepatitis/100 000* | Completion (%) | Comments |
|---|---|---|---|---|
| H, isoniazid; R, Rifampicin; Z, Pyrazinamide. | ||||
| *Symptomatic or grade 3/4 hepatitis. | ||||
| Regimen: Isoniazid (6H) | ||||
| IUATLD16 | 6965 | 480 | 78 | 65% protective efficacy (1 death from 6H) |
| Jasmer et al21 | 282 | 1000 | 59 | |
| Nolan et al22 | 11141 | 100 | – | Female OR 3.3 (0.87 to 12.45) |
| White OR 2.60 (0.75 to 8.95) | ||||
| Increase with age χ2 = 5.22 | ||||
| Bailey et al23 | 427 | 1170 | – | |
| Weighted average | 18815 | 278 | ||
| Regimen: Rifampicin/isoniazid (3RH) | ||||
| Hong Kong Chest Service et al24 | 170 | 1766 | – | 50% protective efficacy in silicosis |
| Regimen: Rifampicin/pyrazinamide (2RZ) | ||||
| Lee et al25 | 148 | 9459 | 57 | Female OR 4.1 (1.2 to 14.3) Recent tuberculin conversion OR 14.3 (1.8 to 115) |
| Jasmer et al21 | 307 | 7700 | 61 | Age >35 OR 12.2 (1.49 to 100.3) |
| OR 8.46 isoniazid (1.9 to 76.5) | ||||
| Stout et al26 | 114 | 5300 | 67.5 | |
| Weighted average | 569 | 6648 | ||